Navigation Links
Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
Date:10/29/2010

ture events, economic, competitive and regulatory conditions, financial market conditions and future business decisions, including, but not limited to: (i) a successful recapitalization transaction; (ii) the absence of a material adverse effect on Angiotech's business on a going forward basis resulting from any recapitalization transaction or otherwise; (iii) a continuation of business arrangements on substantially the same basis as existed prior to the recapitalization transaction; (iv) the availability of liquidity and capital resources in the future to fund certain investments in sales, marketing, working capital and research and development; and (v) Angiotech's estimates as to future product sales, royalty revenue and estimates of operating expenses and working capital necessary to support Angiotech's various business initiatives.

The results, estimates, projections, events or other forward looking information predicted in any forward looking statements may differ materially from actual results or events.  Known or unknown risks, trends or uncertainties may affect Angiotech's businesses.  In addition, the information in this news release does not contemplate the outcome if Angiotech is unable to complete the proposed recapitalization transaction or is unable to generate or access additional liquidity and capital resources to support its business and investment initiatives, and therefore pursues alternative options such as a prolonged Companies' Creditors Arrangement Act (Canada) ("CCAA") proceeding or other similar proceedings. 

Angiotech has developed the following financial projections for its Base Medical Products Segment and its Proprietary Medical Products Segment.  The following projections are not comparable with historical business unit revenue figures as reported in prior quarterly results, as certain products included in our Proprietary Medical segment in our previous historical results have been included as
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
2. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
3. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
4. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
5. Angiotech Pharmaceuticals announces time change of conference call and webcast
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
8. Angiotech announces positive results from Bio-Seal(TM) clinical study
9. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
10. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
11. Angiotech announces date of annual general meeting of shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Mass. , Dec. 18, 2014  Decision Resources ... dental biomaterial market will grow moderately through 2023 ... procedures and growing awareness of dental biomaterials all spur ... markets such as China and ... will bring dental procedures within reach for a larger ...
(Date:12/17/2014)... NY (PRWEB) December 16, 2014 The ... changes since 2013, which is why IBISWorld updated its ... industry continues to benefit from an intensified focus on ... proposal for new emission standards for power plants and ... operators. According to IBISWorld Industry Analyst Sarah Kahn, “a ...
(Date:12/17/2014)... RIDGE, N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today ... mg (referred to as Somatuline®) was approved by ... the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ... locally advanced or metastatic disease to improve progression-free ...
(Date:12/17/2014)... Park, CA (PRWEB) December 17, 2014 ... announces today that it has entered into a ... Midland Company (ADM) to apply DNA2.0’s proprietary protein ... enzyme engineering process. , “We are extremely excited ... ProteinGPS engineering platform. This proprietary bioengineering technology ...
Breaking Biology Technology:Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... stock held by American Red Cross, in a ... in PRDT to 77%, - American Red Cross to ... MONTREAL and CAMBRIDGE, England, April 9 /PRNewswire-FirstCall/ -,ProMetic ... a Letter of Intent ("LOI") to acquire the American ...
... April 9 Francis S. Collins, M.D., ... Genome Project, has been named,recipient of the ... Center for Ethics and Excellence at Case ... ), The Inamori Ethics Prize honors ...
... Genetic Engineering,and Biotechnology News (GEN), http://www.genengnews.com ... on New Polymeric Drug Delivery Systems, on,Thursday, April ... is institute professor, chemical and biomedical engineering,Massachusetts Institute ... innovator in modern drug delivery," says John Sterling,Editor-in-Chief ...
Cached Biology Technology:ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 2ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 3ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 4ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 5ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 6ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 7Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 2Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 3Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 4Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems 2
(Date:12/19/2014)... 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... in July 2012, Apple introduced the fingerprint reading ... the only device of Apple incorporating such a ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and ... addition of the "Micro Market Monitor: North America ... http://photos.prnewswire.com/prnh/20130307/600769 ... grow at a CAGR of 3.6% from 2014 to ... in this market, Canada is ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... (Tuesday, April 1, 2008) Identifying genes that ... mouse used to be a monumental task. New ... effective for even the smallest laboratories. This months ... www.cshprotocols.org/TOCs/toc4_08.dtl ) highlights a method for screening the mouse ...
... be the cruelest month? , ... reminiscent of 1993 and 1994, back-to-back years of serious flooding, with ... damage, damaging and destroying more than 50,000 homes and killing at ... Parallels this year include abnormally high levels of precipitation ...
... Like sentinels at their posts, an array of buoys ... on duty in the Stellwagen Bank National Marine Sanctuary ... months, recording sounds from whales, fish, ships and other ... will analyze the biological sounds to help develop a ...
Cached Biology News:Cold Spring Harbor Protocols features methods to screen genomes and analyze evolution 2Geologist decries floodplain development 2Geologist decries floodplain development 3Researchers to develop ocean sanctuary 'noise budget' to evaluate potential impact on marine mammals 2Researchers to develop ocean sanctuary 'noise budget' to evaluate potential impact on marine mammals 3
Human TFPI Affinity Purified Polyclonal Ab Protein Family: Coagulation, Inflammation, Serine Protease Regulators...
Prostaglandin E2 Luminex Standard Product Lines: Unspecified...
Rabbit polyclonal to HMGB1 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 3146 SwissProtID: P09429...
Eppendorf tube holder, for Tube rack 175 x 12 mm, 100. Category: Chromatography Systems & Accessories, Systems....
Biology Products: